$POAI
Predictive Oncology Inc.

2017 Q4 Form 10-K Financial Statement

#000117184318002453 Filed on April 02, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $220.0K $654.8K $140.0K
YoY Change 57.14% 43.45% -22.22%
Cost Of Revenue $60.00K $148.0K $30.00K
YoY Change 100.0% -18.49% -70.0%
Gross Profit $160.0K $506.8K $110.0K
YoY Change 45.45% 84.37% 37.5%
Gross Profit Margin 72.73% 77.39% 78.57%
Selling, General & Admin $500.0K $5.146M $610.0K
YoY Change -18.03% -8.81% -67.38%
% of Gross Profit 312.5% 1015.32% 554.55%
Research & Development $289.0K
YoY Change -28.82%
% of Gross Profit 57.03%
Depreciation & Amortization $20.00K $71.56K $20.00K
YoY Change 0.0% -13.11% 0.0%
% of Gross Profit 12.5% 14.12% 18.18%
Operating Expenses $1.340M $6.054M $840.0K
YoY Change 59.52% 0.08% -64.26%
Operating Profit -$1.180M -$5.547M -$730.0K
YoY Change 61.64% -3.93% -67.84%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $50.00K $50.00K
YoY Change
Pretax Income -$1.130M -$6.000M -$730.0K
YoY Change 54.79% -8.12% -67.7%
Income Tax
% Of Pretax Income
Net Earnings -$1.130M -$6.000M -$730.0K
YoY Change 54.79% -8.12% -67.7%
Net Earnings / Revenue -513.64% -916.26% -521.43%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.712M -$9.375M -$1.622M
COMMON SHARES
Basic Shares Outstanding 6.363M
Diluted Shares Outstanding 6.363M

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.010M $1.010M $2.150M
YoY Change -53.02% -53.02% -55.76%
Cash & Equivalents $766.2K $1.764M
Short-Term Investments $240.0K $240.0K $380.0K
Other Short-Term Assets $290.0K $290.0K $150.0K
YoY Change 93.33% 93.33% -44.44%
Inventory $265.0K $270.0K $272.2K
Prepaid Expenses
Receivables $137.5K $140.0K $38.92K
Other Receivables $670.0K $670.0K $0.00
Total Short-Term Assets $2.371M $2.370M $2.608M
YoY Change -9.09% -9.2% -51.68%
LONG-TERM ASSETS
Property, Plant & Equipment $87.72K $90.00K $101.5K
YoY Change -13.58% -10.0% -27.29%
Goodwill
YoY Change
Intangibles $95.36K $97.87K
YoY Change -2.57% 3.03%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.253M $1.250M $199.4K
YoY Change 528.54% 525.0% -15.01%
TOTAL ASSETS
Total Short-Term Assets $2.371M $2.370M $2.608M
Total Long-Term Assets $1.253M $1.250M $199.4K
Total Assets $3.624M $3.620M $2.808M
YoY Change 29.09% 28.83% -50.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $140.5K $140.0K $220.1K
YoY Change -36.19% -36.36% -66.16%
Accrued Expenses $785.2K $790.0K $1.346M
YoY Change -41.67% -41.48% 55.75%
Deferred Revenue $6.663K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $932.3K $930.0K $1.574M
YoY Change -40.77% -40.76% 3.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $310.0K
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $310.0K
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $932.3K $930.0K $1.574M
Total Long-Term Liabilities $0.00 $0.00 $310.0K
Total Liabilities $932.3K $930.0K $1.884M
YoY Change -50.51% -50.53% 23.96%
SHAREHOLDERS EQUITY
Retained Earnings -$53.02M -$47.02M
YoY Change 12.77% 16.12%
Common Stock $69.43K $45.64K
YoY Change 52.12% 2094.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.692M $2.690M $923.7K
YoY Change
Total Liabilities & Shareholders Equity $3.624M $3.620M $2.808M
YoY Change 29.09% 28.83% -50.15%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$1.130M -$6.000M -$730.0K
YoY Change 54.79% -8.12% -67.7%
Depreciation, Depletion And Amortization $20.00K $71.56K $20.00K
YoY Change 0.0% -13.11% 0.0%
Cash From Operating Activities -$1.320M -$4.460M -$680.0K
YoY Change 94.12% 1.79% -76.14%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $45.09K -$10.00K
YoY Change 0.0% 37.65% -75.0%
Acquisitions
YoY Change
Other Investing Activities $30.00K -$1.600M $190.0K
YoY Change -84.21% 321.05%
Cash From Investing Activities $30.00K -$1.653M $180.0K
YoY Change -83.33% 290.93% -550.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.815M
YoY Change 122.81%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.300M 5.115M 1.620M
YoY Change -19.75% 198.74% 16100.0%
NET CHANGE
Cash From Operating Activities -1.320M -4.460M -680.0K
Cash From Investing Activities 30.00K -1.653M 180.0K
Cash From Financing Activities 1.300M 5.115M 1.620M
Net Change In Cash 10.00K -997.9K 1.120M
YoY Change -99.11% -67.73% -138.89%
FREE CASH FLOW
Cash From Operating Activities -$1.320M -$4.460M -$680.0K
Capital Expenditures -$10.00K $45.09K -$10.00K
Free Cash Flow -$1.310M -$4.505M -$670.0K
YoY Change 95.52% 2.05% -76.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 aipt Valuation Allowance Percentage
ValuationAllowancePercentage
1
CY2016 aipt Stock Issued During Period Value Preferred Stock Conversion
StockIssuedDuringPeriodValuePreferredStockConversion
0
CY2015Q3 aipt Underwriter Price
UnderwriterPrice
8.28
CY2015Q3 aipt Underwriting Agreement Nonaccountable Expense Allowance Percentage
UnderwritingAgreementNonaccountableExpenseAllowancePercentage
0.01
CY2015Q3 aipt Underwriting Commission
UnderwritingCommission
0.08
CY2017Q4 aipt Class Of Warrant Or Right Number Of Warrants Vested And Exercisable
ClassOfWarrantOrRightNumberOfWarrantsVestedAndExercisable
1253311
CY2016 aipt Corrections Due To Rounding For Reverse Stock Split Value
CorrectionsDueToRoundingForReverseStockSplitValue
-1
CY2017 aipt Defined Contribution Plan Employer Contribution Amount
DefinedContributionPlanEmployerContributionAmount
29952
CY2016 aipt Defined Contribution Plan Employer Contribution Amount
DefinedContributionPlanEmployerContributionAmount
33143
CY2017 aipt Equity Instruments Issued For Management And Consulting
EquityInstrumentsIssuedForManagementAndConsulting
359133
CY2016 aipt Equity Instruments Issued For Management And Consulting
EquityInstrumentsIssuedForManagementAndConsulting
721330
CY2017 aipt Operating And Nonoperating Expense Total
OperatingAndNonoperatingExpenseTotal
8253384
CY2016 aipt Operating And Nonoperating Expense Total
OperatingAndNonoperatingExpenseTotal
6800889
CY2015Q3 aipt Option Granted To Underwriter To Purchase Additional Units Number Of Units Granted
OptionGrantedToUnderwriterToPurchaseAdditionalUnitsNumberOfUnitsGranted
250000
CY2015Q3 aipt Option Granted To Underwriter To Purchase Additional Units Period
OptionGrantedToUnderwriterToPurchaseAdditionalUnitsPeriod
P45D
CY2017 aipt Proceeds From Redemption Of Certificates Of Deposits
ProceedsFromRedemptionOfCertificatesOfDeposits
2940000
CY2016 aipt Proceeds From Redemption Of Certificates Of Deposits
ProceedsFromRedemptionOfCertificatesOfDeposits
1000000
CY2017Q2 aipt Reverse Shares Issued For Escrow Pursuant To Termination Of Agreement Shares
ReverseSharesIssuedForEscrowPursuantToTerminationOfAgreementShares
400000
CY2017 aipt Reverse Shares Issued For Escrow Under Termination Of Agreement Value
ReverseSharesIssuedForEscrowUnderTerminationOfAgreementValue
4000
CY2015Q3 aipt Underwriting Discount
UnderwritingDiscount
0.72
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
309649
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
140462
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
220112
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
137499
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38919
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
785215
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1346105
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
273770
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
214897
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1501
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57380256
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47894196
CY2017 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
CY2016 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
736725
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
165271
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4042256
CY2017 us-gaap Advertising Expense
AdvertisingExpense
37060
CY2016 us-gaap Advertising Expense
AdvertisingExpense
71212
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1892159
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
165271
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12689
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9107
CY2017Q4 us-gaap Assets
Assets
3624254
CY2016Q4 us-gaap Assets
Assets
2807546
CY2017Q4 us-gaap Assets Current
AssetsCurrent
2371182
CY2016Q4 us-gaap Assets Current
AssetsCurrent
2608183
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
284329
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
1837
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
4716
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
766189
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1764090
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4856232
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4564428
CY2017 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-997901
CY2016 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-3092142
CY2017Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
563000
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
244971
CY2016Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
100000
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1951257
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
8000000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
24000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6943283
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6943283
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
69432
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
45644
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7746593
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6524513
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Credit Risk </div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. The Company had a credit risk concentration as a result of depositing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$563,000</div> of funds in excess of insurance limits in a single bank.</div></div></div></div></div></div></div></div>
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
148045
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
181620
us-gaap Debt Instrument Increase Decrease For Period Net
DebtInstrumentIncreaseDecreaseForPeriodNet
5685000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6663
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7998
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7608943
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10944000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7393100
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10755000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
215843
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
189000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7608943
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10944000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.04
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.04
CY2017 us-gaap Depreciation
Depreciation
58872
CY2016 us-gaap Depreciation
Depreciation
73249
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
71562
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82356
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.31
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1139172
CY2016 us-gaap Gross Profit
GrossProfit
274875
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2387
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6041485
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5174799
CY2017 us-gaap Gross Profit
GrossProfit
506791
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-79650
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-430301
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
98580
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
636
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-870540
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
791459
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1335
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2998
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-7163
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
40468
CY2017 us-gaap Increase Decrease In Notes Receivable Current
IncreaseDecreaseInNotesReceivableCurrent
1737512
CY2016 us-gaap Increase Decrease In Notes Receivable Current
IncreaseDecreaseInNotesReceivableCurrent
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
141329
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-122943
CY2017 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2016 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
95356
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
97867
CY2017 us-gaap Interest Expense
InterestExpense
CY2016 us-gaap Interest Expense
InterestExpense
3
CY2017 us-gaap Interest Paid Net
InterestPaidNet
0
CY2016 us-gaap Interest Paid Net
InterestPaidNet
3
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
62932
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
38201
CY2017Q4 us-gaap Inventory Net
InventoryNet
265045
CY2016Q4 us-gaap Inventory Net
InventoryNet
272208
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
141028
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
165812
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
61085
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
68195
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
66122
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
66239
CY2017Q4 us-gaap Liabilities
Liabilities
932340
CY2016Q4 us-gaap Liabilities
Liabilities
1883864
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3624254
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2807546
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
932340
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1574215
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5114939
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1712158
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1653090
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-422860
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4459750
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
39000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4381440
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7746593
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6526014
CY2017Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
667512
CY2016Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
CY2017Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
1070000
CY2016Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2017 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1207724
CY2016 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1158117
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
42000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
40000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1501
CY2017 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
CY2016 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
850000
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10179
CY2016 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
11987
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45093
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32760
CY2017 us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
3084971
CY2016 us-gaap Payments To Acquire Restricted Certificates Of Deposit
PaymentsToAcquireRestrictedCertificatesOfDeposit
1100000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
289966
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
148637
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3814938
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1712158
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
1300001
CY2016 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
CY2015Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13800000
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
284665
CY2016 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
571887
CY2017 us-gaap Product Warranty Expense
ProductWarrantyExpense
6209
CY2016 us-gaap Product Warranty Expense
ProductWarrantyExpense
34665
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
361486
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
316393
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87716
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101496
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
289000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
406000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54765045
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47018451
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
654836
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
456495
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
65.75
CY2016Q3 us-gaap Share Price
SharePrice
4.125
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y164D
CY2015Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
9
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
923682
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
4112711
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1004175
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
467970
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4042256
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
165271
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.66
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.66
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.59
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.59
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2764983
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1728264
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.29
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
1900000
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
400000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
86182
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3421188
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
86253
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2691914
us-gaap Stockholders Equity Period Increase Decrease
StockholdersEquityPeriodIncreaseDecrease
29065934
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Accounting Policies and Estimates</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6362989
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2823345
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6362989
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2823345

Files In Submission

Name View Source Status
0001171843-18-002453-index-headers.html Edgar Link pending
0001171843-18-002453-index.html Edgar Link pending
0001171843-18-002453.txt Edgar Link pending
0001171843-18-002453-xbrl.zip Edgar Link pending
aipt-20171231.xml Edgar Link completed
aipt-20171231.xsd Edgar Link pending
aipt-20171231_cal.xml Edgar Link unprocessable
aipt-20171231_def.xml Edgar Link unprocessable
aipt-20171231_lab.xml Edgar Link unprocessable
aipt-20171231_pre.xml Edgar Link unprocessable
exh_231.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10k_040218p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending